ANDA 65301, held by Chartwell Rx. Cefadroxil/Cefadroxil Hemihydrate.
As of Nov 16, 2026, ANDA 65301 (Cefadroxil), held by Chartwell Rx, was first approved by FDA on Sep 18, 2006, with 1 approved supplement and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Sep 18, 2006 | Original application | Approved | None posted |
| Product | Active ingredient | Marketing |
|---|---|---|
| CefadroxilEQ 1GM BASE · tablet;oral | Cefadroxil/Cefadroxil Hemihydrate | Discontinued |
| Apr 18, 2014 | Supplement 3Labeling · Standard review | Approved | None posted |
| Sep 18, 2006 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters